KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Prepaid Assets: 2020-2024

Historic Prepaid Assets for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Dec 2024 value amounting to $38.1 million.

  • Recursion Pharmaceuticals' Prepaid Assets fell 31.59% to $29.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.2 million, marking a year-over-year decrease of 31.59%. This contributed to the annual value of $38.1 million for FY2024, which is 5.32% down from last year.
  • Per Recursion Pharmaceuticals' latest filing, its Prepaid Assets stood at $38.1 million for FY2024, which was down 5.32% from $40.2 million recorded in FY2023.
  • Recursion Pharmaceuticals' Prepaid Assets' 5-year high stood at $40.2 million during FY2023, with a 5-year trough of $2.2 million in FY2020.
  • Its 3-year average for Prepaid Assets is $31.4 million, with a median of $38.1 million in 2024.
  • In the last 5 years, Recursion Pharmaceuticals' Prepaid Assets soared by 248.68% in 2021 and then dropped by 5.32% in 2024.
  • Over the past 5 years, Recursion Pharmaceuticals' Prepaid Assets (Yearly) stood at $2.2 million in 2020, then spiked by 248.68% to $7.5 million in 2021, then spiked by 111.19% to $15.9 million in 2022, then surged by 153.62% to $40.2 million in 2023, then decreased by 5.32% to $38.1 million in 2024.